临床团队： 肝病与肿瘤介入治疗中心是以患者获益为目标，以微创介入诊疗技术为核心，开展肝病与肿瘤的多学科诊疗和个体化、精准治疗。从精准诊断，精准治疗，到个体化随访方案，为多部位实体肿瘤实行多种微创手术治疗模式。对早期实体肿瘤可完全清除；对不能外科手术切除的中晚期肿瘤，应用多种微创消融手术联合动脉导管栓塞、靶免治疗等综合治疗，也可使多数患者获得根治性治疗效果。每年微创介入手术量约9000台，居全国前列。承担多项国家级、省部市级课题，创建国家肿瘤微创产业技术创新战略联盟，撰写《肿瘤消融治疗技术管理规范》等多项规范和行业标准。承担首都医科大学研究生课程及国家继续教育课程，获批 “国家肿瘤消融治疗技术培训基地”称号。

铅衣军团欢迎勇于挑战的你

转化团队：传染病相关疾病生物标志物北京市重点实验室以首都医科大学附属北京佑安医院为依托，北京市科学技术委员会认定的北京市重点实验室，以传染病及相关疾病的临床诊断生物标志物研究为方向，研究疾病的早期诊断和早期治疗。运用现代高通量检测技术，与临床治疗相结合，实现基础科学研究与临床诊断和治疗的转化，发现并提出相关疾病特异性、敏感性的早期诊断和治疗标志物，为疾病的治疗和人类健康提供帮助。目前DNA甲基化检测技术、代谢组学检测技术在临床科研中的应用取得了优秀的成果，获得多项专利及发表多篇SCI论文。

Beijing Key Lab of Biomarker for Infection Related Diseases (Bird)为开拓创新的你提供展翅翱翔的平台

在研课题：

1、北京自然科学基金重点项目：乙肝相关肝癌外周血DNA甲基化谱变化规律研究（7191004），2019-2022.

2、首都卫生发展专项重点攻关：基于DNA甲基化和代谢组学的乙肝相关肝癌早期诊断标志物研究（首发2020-2182），2020-2023.

在研课题：

1、北京自然科学基金重点项目：乙肝相关肝癌外周血DNA甲基化谱变化规律研究（7191004），2019-2022.

2、首都卫生发展专项重点攻关：基于DNA甲基化和代谢组学的乙肝相关肝癌早期诊断标志物研究（首发2020-2182），2020-2023.

近五年发表论文：

1.    The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy. Wang Q, Qiao W, Liu B, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. BMC Gastroenterol. 2022 Mar 4;22(1):98. 

2.    The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study. Wang Q, Liu B, Qiao W, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. Front Oncol. 2021 Dec 16;11:756363. Q2 IF=6.244

3.    Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y.BMC Cancer. 2021 Sep 8;21(1):1007. Q2 IF=4.43

4.    A CpG Methylation Signature as a Potential Marker for Early Diagnosis of Hepatocellular Carcinoma From HBV-Related Liver Disease Using Multiplex Bisulfite Sequencing. Li K, Song Y, Qin L, Li A, Jiang S, Ren L, Zang C, Sun J, Zhao Y, Zhang Y. Front Oncol. 2021 Oct 20;11:756326. Q2 IF=6.244

5.    A Nomogram Prediction of Length of Hospital Stay in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study. Li K, Zhang C, Qin L, Zang C, Li A, Sun J, Zhao Y, Feng Y, Zhang Y.Dis Markers. 2021 Jun 7;2021:5598824. Q2 IF=3.434

6.    Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma. Hou Y, Wang S, Gao M, Chang J, Sun J, Qin L, Li A, Lv F, Lou J, Zhang Y, Zhao Y.Biomed Res Int. 2021 Mar 16;2021:5612138. Q3 IF=3.411

7.    Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. Zhang Y, Qin L, Zhao Y, Zhang P, Xu B, Li K, Liang L, Zhang C, Dai Y, Feng Y, Sun J, Hu Z, Xiang H, Knight JC, Dong T, Jin R.J Infect Dis. 2020 Jun 16;222(1):34-37. Q1 IF=5.226

8.    Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, Xu B, Dai Y, Li X, Zhang C, Peng Y, Feng Y, Li A, Hu Z, Xiang H, Ogg G, Ho LP, McMichael A, Jin R, Knight JC, Dong T, Zhang Y.JCI Insight. 2020 Jul 9;5(13):e139834. Q1 IF=8.315

9.    A Novel Scoring System for Prediction of Disease Severity in COVID-19. Zhang C, Qin L, Li K, Wang Q, Zhao Y, Xu B, Liang L, Dai Y, Feng Y, Sun J, Li X, Hu Z, Xiang H, Dong T, Jin R, Zhang Y.Front Cell Infect Microbiol. 2020 Jun 5;10:318. Q1 IF=5.293

10. The signature of HBV-related liver disease in peripheral blood mononuclear cell DNA methylation. Li K, Qin L, Jiang S, Li A, Zhang C, Liu G, Sun J, Sun H, Zhao Y, Li N, Zhang Y. Clin Epigenetics. 2020 Jun 8;12(1):81. Q2 IF=6.551

11. Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma. Zhao Y, Li K, Sun J, He N, Zhao P, Zang C, Yang X, Hu C, Long J, Zhang H, Wang Q, Zhao Y, Zhang Y.Oncol Lett. 2020 Jul;20(1):677-684. Q4 IF=2.967

12. Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes. Sun J, Zhao Y, Qin L, Li K, Zhao Y, Sun H, Zhang T, Zhang Y.Front Oncol. 2019 Oct 15;9:1069. Q2 IF=6.244

13. A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies. Wang Q, Ma L, Li J, Yuan C, Sun J, Li K, Qin L, Zang C, Zhao Y, Zhao Y, Zhang Y.Cancer Manag Res. 2019 Dec 20;11:10641-10649. Q3 IF=3.989

14. The signature of liver cancer in immune cells DNA methylation. Zhang Y, Petropoulos S, Liu J, Cheishvili D, Zhou R, Dymov S, Li K, Li N, Szyf M.Clin Epigenetics. 2018 Jan 18;10:8. Q2 IF=6.551

15. T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell. Liu S, Sun J, Li Z, Qin L, Liu G, Li K, Wu H, Dong T, Zhang Y. Front Immunol. 2019 Mar 18;10:437. Q2 IF=7.561

16. Quality of Cryopreserved Peripheral Blood Mononuclear Cells Recovered from the Hepatitis/AIDS Biobank.Sun J, Gao M, Li K, Qin L, Sun H, Qiao G, Zhao Y, Zhang Y.Biopreserv Biobank. 2018 Dec;16(6):397-401. Q4 IF=2.3

17. High Level Antibody Response to Pandemic Influenza H1N1/09 Virus Is Associated With Interferon-Induced Transmembrane Protein-3 rs12252-CC in Young Adults. Qin L, Wang D, Li D, Zhao Y, Peng Y, Wellington D, Dai Y, Sun H, Sun J, Liu G, McMichael A, Dong T, Zhang Y. Front Cell Infect Microbiol. 2018 May 15;8:134. Q2 IF=5.293

18. Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases. Sun L, Li K, Liu G, Xu Y, Zhang A, Lin D, Zhang H, Zhao X, Jin B, Li N, Zhang Y.Cancer Med. 2018 Oct;7(10):5178-5186. Q3 IF=4.452